CN103313730B - 用于治疗癌症的肽靶向系统的组合物 - Google Patents

用于治疗癌症的肽靶向系统的组合物 Download PDF

Info

Publication number
CN103313730B
CN103313730B CN201180059699.3A CN201180059699A CN103313730B CN 103313730 B CN103313730 B CN 103313730B CN 201180059699 A CN201180059699 A CN 201180059699A CN 103313730 B CN103313730 B CN 103313730B
Authority
CN
China
Prior art keywords
polypeptide
cell
sirna
domain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180059699.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103313730A (zh
Inventor
T.普利米亚诺
B-D.张
J.黑德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NanoOncology Inc
Original Assignee
NanoOncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NanoOncology Inc filed Critical NanoOncology Inc
Publication of CN103313730A publication Critical patent/CN103313730A/zh
Application granted granted Critical
Publication of CN103313730B publication Critical patent/CN103313730B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180059699.3A 2010-11-01 2011-11-01 用于治疗癌症的肽靶向系统的组合物 Expired - Fee Related CN103313730B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45612710P 2010-11-01 2010-11-01
US61/456,127 2010-11-01
PCT/US2011/058856 WO2012061443A2 (en) 2010-11-01 2011-11-01 Compositions of a peptide-based system for cell-specific targeting

Publications (2)

Publication Number Publication Date
CN103313730A CN103313730A (zh) 2013-09-18
CN103313730B true CN103313730B (zh) 2016-06-01

Family

ID=44971106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180059699.3A Expired - Fee Related CN103313730B (zh) 2010-11-01 2011-11-01 用于治疗癌症的肽靶向系统的组合物

Country Status (10)

Country Link
US (2) US8680045B2 (https=)
EP (1) EP2635308A2 (https=)
JP (2) JP6189215B2 (https=)
KR (1) KR20130103562A (https=)
CN (1) CN103313730B (https=)
AU (2) AU2011323508B2 (https=)
BR (1) BR112013010911A2 (https=)
CA (1) CA2816584A1 (https=)
SG (2) SG190088A1 (https=)
WO (1) WO2012061443A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015003021A2 (en) 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
SG11201701402QA (en) 2014-08-27 2017-03-30 Peptimed Inc Anti-tumor compositions and methods
CA2970478A1 (en) 2014-12-10 2016-06-16 S-Aima Holding Company, Llc Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
RU2019110848A (ru) 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
CN106822036B (zh) * 2016-12-15 2022-08-09 国家纳米科学中心 特异靶向多肽自组装纳米载体、载药纳米颗粒及制备方法
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018175899A1 (en) * 2017-03-24 2018-09-27 The Regents Of The University Of Colorado, A Body Corporate Targeted nanogels for urinary bladder therapies
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
WO2020081716A2 (en) * 2018-10-16 2020-04-23 Texas Tech University System Biomaterials for 3d cell growth and differentiation
EP3996684A4 (en) * 2019-07-09 2024-06-19 Ariz Precision Medicine, Inc. CANCER TREATMENT USING TARGETED PHARMACEUTICAL SIRNA FORMULATIONS TO DECREASE THE EXPRESSION OF THE PRDM14 PROTEIN
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
CN116113421A (zh) 2020-05-14 2023-05-12 阿莱兹精准医疗公司 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗
CN117138067A (zh) * 2022-05-23 2023-12-01 安徽医科大学 99mTc-DOTA-GVR及其制备方法与应用
EP4644412A1 (en) * 2022-12-27 2025-11-05 NexThera Co., Ltd. Manufacture of elastin-like polypeptide-based recombinant protein and animal cell expression platform thereof
CN120019823A (zh) * 2023-11-20 2025-05-20 湖南中晟全肽生物科技股份有限公司 一种放射性标记的类弹性蛋白多肽及其制备方法和应用
WO2026005476A1 (ko) * 2024-06-26 2026-01-02 주식회사 넥스세라 혈소판 감소증 치료를 위한 재조합 단백질 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045243A3 (en) * 2005-10-17 2007-10-18 Enkam Pharmaceuticals As Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
JP2003528024A (ja) 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
WO2001025422A2 (en) 1999-10-07 2001-04-12 Avi Biopharma, Inc. Antisense compositions and cancer-treatment methods
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
CA2411600A1 (en) * 2000-06-09 2001-12-13 Ipk Institut Fur Pflanzenzengenetik Und Kulturplanzenforschung Synthetic spider silk proteins and the expression thereof in transgenic plants
US20050037445A1 (en) * 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP3725299A1 (en) * 2005-06-24 2020-10-21 Duke University A direct drug delivery system based on thermally responsive biopolymers
US20100119529A1 (en) * 2006-05-12 2010-05-13 Furgeson Darin Y Elastin-like polymer delivery vehicles
US8241623B1 (en) * 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045243A3 (en) * 2005-10-17 2007-10-18 Enkam Pharmaceuticals As Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin》;Bidwell et al.;《Biochemical Pharmacology》;20070130;第73卷(第5期);摘要，图1 *

Also Published As

Publication number Publication date
US9358308B2 (en) 2016-06-07
AU2017208213A1 (en) 2017-08-10
AU2011323508A1 (en) 2013-06-13
CA2816584A1 (en) 2012-05-10
WO2012061443A2 (en) 2012-05-10
JP2014504150A (ja) 2014-02-20
WO2012061443A3 (en) 2012-08-23
JP2016171801A (ja) 2016-09-29
US20140220045A1 (en) 2014-08-07
CN103313730A (zh) 2013-09-18
AU2011323508B2 (en) 2017-04-27
BR112013010911A2 (pt) 2017-05-02
US20120208742A1 (en) 2012-08-16
SG190088A1 (en) 2013-06-28
KR20130103562A (ko) 2013-09-23
US8680045B2 (en) 2014-03-25
JP6189215B2 (ja) 2017-08-30
EP2635308A2 (en) 2013-09-11
SG10201508981YA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
CN103313730B (zh) 用于治疗癌症的肽靶向系统的组合物
CN103403189B (zh) 用于稳定的多价RNA纳米颗粒中的pRNA多价连接域
CN103501818A (zh) 用于高效及靶向递送治疗性分子至cxcr4细胞的方法和试剂
Zhao et al. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
US20220143197A1 (en) siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer
US10266820B2 (en) RNA/DNA nanoparticle for siRNA target-specific delivery and vehicle including the same
JP2016180011A (ja) がんを治療するための試薬および方法
WO2015164666A1 (en) Nanoparticles for targeted gene therapy and methods of use thereof
KR101253261B1 (ko) ｓｉＲＮＡ 의 전달을 위한 재조합 단백질 및 이를 포함하는 조성물
KR20220117091A (ko) 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도
JP4852539B2 (ja) 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
Yin et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo
KR20080041037A (ko) 단백질 수송 펩타이드와 짧은 간섭 ｒｎａ와의 복합체 및그 용도
Cultrara Applications of siRNA for Cancer Gene Therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160601

Termination date: 20171101